Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.
Victor MorenoE CalvoM R MiddletonF BarlesiC Gaudy-MarquesteA ItalianoE RomanoA MarabelleE ChartashK DobrenkovH ZhouE C ConnorsY ZhangM WermkePublished in: Cancer immunology, immunotherapy : CII (2022)
ClinicalTrials.gov, NCT03065023 and NCT03739138.